{
    "clinical_study": {
        "@rank": "112489", 
        "arm_group": [
            {
                "arm_group_label": "Part A, arm 1", 
                "arm_group_type": "Experimental", 
                "description": "Evening dose of TF048. Morning dose of TF043"
            }, 
            {
                "arm_group_label": "Part A, arm 2", 
                "arm_group_type": "Experimental", 
                "description": "Evening dose of TF043. Morning dose of TF048"
            }, 
            {
                "arm_group_label": "Part A, arm 3", 
                "arm_group_type": "Experimental", 
                "description": "Evening dose of TF047. Morning dose of TF043"
            }, 
            {
                "arm_group_label": "Part A, arm 4", 
                "arm_group_type": "Active Comparator", 
                "description": "MOVIPREP (Both evening and morning dose)"
            }, 
            {
                "arm_group_label": "Part B, arm 1", 
                "arm_group_type": "Experimental", 
                "description": "IMP selected based on the optimal dosing sequence and volume identified from Part A"
            }, 
            {
                "arm_group_label": "Part B, arm 2", 
                "arm_group_type": "Experimental", 
                "description": "IMP as used in Part B, arm 1, with a differing amount of additional clear fluid being consumed"
            }, 
            {
                "arm_group_label": "Part B, arm 3", 
                "arm_group_type": "Active Comparator", 
                "description": "IMP as used in Part B, arm 1, except for a reduced amount of ascorbate"
            }, 
            {
                "arm_group_label": "Part B, arm 4", 
                "arm_group_type": "Experimental", 
                "description": "MOVIPREP used in both evening and morning dose"
            }
        ], 
        "brief_summary": {
            "textblock": "A study to assess the pharmacodynamics, safety and tolerability of a PEG-based bowel\n      cleansing solution (MOVIPREP\u00ae)"
        }, 
        "brief_title": "Pharmacodynamic and Clinical Evaluation of Dose and Taste-optimised Low Volume PEG-based Bowel Cleansing Solutions Using the Split-dosing Intake Regimen in Healthy Subjects and in Subjects Undergoing Screening Colonoscopy", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Colon Cancer", 
        "condition_browse": {
            "mesh_term": "Colonic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The subject's written informed consent must be obtained prior to inclusion.\n\n          -  Subjects age 40 to 70 years.\n\n          -  Part B only: Subjects willing to undergoing a screening colonoscopy, where the\n             subject:\n\n               1. is between 40 and 70 years of age and has a known personal or familial risk of\n                  colon neoplasia,or\n\n               2. is aged 55 to 70.\n\n          -  Part A: Subjects need to be without any history of clinically significant\n             gastrointestinal symptoms by clinical judgement and without the presence of acute\n             abdominal discomfort or symptoms.\n\n          -  Females of child bearing potential must be surgically sterile, post- menopausal,\n             practicing true sexual abstinence or using an acceptable form of effective\n             contraception throughout the study from the following list: contraceptive injections,\n             implants, oral contraceptives, intrauterine system (IUS), some intrauterine devices\n             (IUDs), vasectomised partner or barrier method (condom or occlusive cap) with\n             spermicidal foam/gel/film/cream/suppository. Females using oral contraceptives must\n             also use additional contraception. Hormonal and IUD methods of contraception must be\n             established for a period of 3 months prior to dosing and cannot be changed or altered\n             during the study. All females must have a negative pregnancy test at screening and\n             check-in (unless post-menopausal).\n\n          -  Willing, able and competent to complete the entire procedure and to comply with study\n             instructions.\n\n          -  Ferrous sulphate should be stopped at least one week prior to study medication.\n\n        Exclusion Criteria:\n\n          -  Part A only: Subjects undergoing screening colonoscopy.\n\n          -  Presence of current clinically significant functional gastrointestinal (GI) disorder\n             (e.g. gastric emptying disorder, chronic constipation, irritable bowel syndrome\n             [IBS]).\n\n          -  Regular use of laxatives or colon motility altering drugs in the last month.\n\n          -  Donation or loss of 500 mL or more of blood within 8 weeks prior to the first dose of\n             investigational drug.\n\n          -  Any history or current presence of ileus, gastrointestinal (GI) obstruction or\n             perforation , GI tract cancer, inflammatory bowel disease (IBD) or colonic resection.\n\n          -  Known glucose-6-phosphatase dehydrogenase deficiency.\n\n          -  Known phenylketonuria.\n\n          -  History or evidence of any clinical significant cardiovascular or neurological\n             disease, cardiac, renal or hepatic insufficiency.\n\n          -  Known hypersensitivity to polyethylene glycols and/or ascorbic acid.\n\n          -  History or evidence of any clinically relevant electrocardiogram (ECG) abnormalities\n             and/or uncontrolled hypertension.\n\n          -  Evidence of dehydration.\n\n          -  Any evidence for clinically significant abnormal sodium or potassium levels or other\n             clinically significant plasma electrolyte disturbances.\n\n          -  Females who are not post-menopausal with a positive pregnancy test. Females not using\n             reliable methods of birth control if not post-menopausal.\n\n          -  Clinically relevant findings on physical examination based on the Investigator's\n             judgement.\n\n          -  Clinically relevant deviations of laboratory parameters from reference ranges at\n             screening or check-in evaluation.\n\n          -  Positive serology for chronic viral hepatitis or human immunodeficiency virus (HIV)\n             at screening.\n\n          -  History of drug or alcohol abuse within the 12 months prior to dosing or evidence of\n             such abuse as indicated by the laboratory assays conducted during the screening or\n             check-in evaluations.\n\n          -  Subjects who are unwilling to comply with the provisions of the study protocol.\n\n          -  Concurrent participation in an investigational drug study or participation within 3\n             months of study entry.\n\n          -  Subject has a condition or is in a situation, which in the Investigator's opinion may\n             put the subject at significant risk, may confound the study results, or may interfere\n             significantly.\n\n          -  Previous participation in the study.\n\n          -  Persons who are ordered to live in an institution on court or authority order"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01714466", 
            "org_study_id": "NER1006-01/2012 (OPT)"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Part A, arm 1", 
                    "Part A, arm 2", 
                    "Part A, arm 3", 
                    "Part B, arm 1", 
                    "Part B, arm 2", 
                    "Part B, arm 3"
                ], 
                "intervention_name": "NER1006", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part A, arm 4", 
                    "Part B, arm 4"
                ], 
                "intervention_name": "MOVIPREP", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 8, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "14050"
                    }, 
                    "name": "Parexel International GmbH"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Rudiger Kornberger, MD", 
                    "phone": "+49 30 30685 3900"
                }, 
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "14050"
                    }, 
                    "name": "PAREXEL International Early Product Development Unit"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "8", 
        "official_title": "Pharmacodynamic and Clinical Evaluation of Dose and Taste-optimised Low Volume PEG-based Bowel Cleansing Solutions Using the Split-dosing Intake Regimen in Healthy Subjects and in Subjects Undergoing Screening Colonoscopy", 
        "overall_contact": {
            "email": "CBay@norgine.com", 
            "last_name": "Caroline Bay", 
            "phone": "+44189545", 
            "phone_ext": "3689"
        }, 
        "overall_official": {
            "affiliation": "PAREXEL International GmbH", 
            "last_name": "Rudiger Kornberger, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Stool weight output generated by the IMP from the start of the intake on the evening of Day 1 and the following 24 hours", 
                "measure": "Stool weight output", 
                "safety_issue": "No", 
                "time_frame": "36 hours post-dose"
            }, 
            {
                "description": "The cleansing success rate (grade A or B according to the Harefield Cleansing Scale)", 
                "measure": "Cleansing success rate", 
                "safety_issue": "No", 
                "time_frame": "36 hours post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01714466"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The patient's tolerability to the study medication by measuring their vomiting rate for both parts A and B", 
                "measure": "Tolerability of medication (vomiting rate)", 
                "safety_issue": "No", 
                "time_frame": "36 hours post-dose"
            }, 
            {
                "description": "Patients to use the EQ 5D patient questionnaire to assess their study medication for part A", 
                "measure": "EQ 5D patient questionnaire outcome (Part A only)", 
                "safety_issue": "No", 
                "time_frame": "36 hours post-dose"
            }, 
            {
                "description": "The segmental cleansing scores for each of the five colon segments", 
                "measure": "Cleansing scores for each colon segment", 
                "safety_issue": "No", 
                "time_frame": "36 hours post-dose"
            }, 
            {
                "description": "The time and volume taken for the IMP to reach a clear effluent", 
                "measure": "Time and volume of IMP to reach a clear effluent", 
                "safety_issue": "No", 
                "time_frame": "36 hours post-dose"
            }, 
            {
                "description": "Concentration of ascorbate components and its metabolites (such as dehydroascorbic acid and oxalic acid)", 
                "measure": "Ascorbate concentration", 
                "safety_issue": "No", 
                "time_frame": "36 hours post-dose"
            }, 
            {
                "description": "Concentration of electrolytes in blood, urine and faeces", 
                "measure": "Electrolytes concentration", 
                "safety_issue": "No", 
                "time_frame": "36 hours post-dose"
            }, 
            {
                "description": "Presence of PEG3350 in faeces, at defined time points, to demonstrate biological activities", 
                "measure": "PEG3350 concentration", 
                "safety_issue": "No", 
                "time_frame": "36 hours post-dose"
            }
        ], 
        "source": "Norgine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Norgine", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}